Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of “Moderate Buy” by Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $5.20.

CNTX has been the subject of several research analyst reports. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research report on Thursday, August 7th. Cantor Fitzgerald began coverage on Context Therapeutics in a report on Thursday. They issued an “overweight” rating for the company. Piper Sandler reiterated an “overweight” rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. HC Wainwright dropped their price target on Context Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, August 7th. Finally, Guggenheim began coverage on Context Therapeutics in a report on Thursday, September 18th. They issued a “buy” rating and a $5.00 target price on the stock.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Context Therapeutics in the fourth quarter worth $29,000. Citadel Advisors LLC purchased a new stake in shares of Context Therapeutics during the fourth quarter worth $31,000. Finally, Millennium Management LLC raised its holdings in shares of Context Therapeutics by 24.2% during the fourth quarter. Millennium Management LLC now owns 178,718 shares of the company’s stock worth $188,000 after acquiring an additional 34,835 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Stock Up 10.0%

Shares of Context Therapeutics stock opened at $1.10 on Friday. The stock’s fifty day moving average is $0.85 and its 200-day moving average is $0.77. The firm has a market capitalization of $98.67 million, a PE ratio of -3.06 and a beta of 1.93. Context Therapeutics has a 12-month low of $0.49 and a 12-month high of $2.59.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Analysts expect that Context Therapeutics will post -0.51 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.